Update on immunotherapy for recurrent pregnancy loss.

Area of Science:

• Reproductive Immunology
• Obstetrics & Gynecology

Background:

• Recurrent spontaneous abortion (RSA) remains a challenge in reproductive medicine.
• Recent clinical trials on immunotherapy for RSA have yielded controversial results regarding efficacy.
• Variations in success rates within control groups (29-76%) necessitate further investigation.

Purpose of the Study:

• To address the controversy surrounding immunotherapy efficacy for recurrent spontaneous abortion (RSA).
• To explore explanations for variable success rates in clinical trials, including sample size and population heterogeneity.
• To investigate alternative immunotherapy approaches beyond husband's leukocyte immunization.

Main Methods:

• Review of recent randomized, placebo-controlled clinical trials on immunotherapy for RSA.
• Proposal for a meta-analysis to investigate variations in trial outcomes.
• Identification of emerging immunotherapy treatments: intravenous immunoglobulin (IVIG) and seminal plasma immunization.

Main Results:

• Clinical trials report a general 70% successful pregnancy rate with immunotherapy for RSA.
• Significant variability in success rates among control populations (29-76%) complicates efficacy assessment.
• Current immunotherapy primarily relies on husband's leukocytes, prompting research into alternatives.

Conclusions:

• The efficacy of immunotherapy for recurrent spontaneous abortion (RSA) is debated due to inconsistent trial results.
• Factors such as small sample sizes and population heterogeneity contribute to outcome variability.
• Further research, including meta-analyses and trials on IVIG and seminal plasma, is crucial to establish safe and effective RSA treatments.